Dr.Lo is a highly experienced medicinal chemist with extensive managerial track record in the pharmaceutical industries in US and China.

Lo, H. Y.* et .al. ˇ°Substituted Pyrazole as Novel sEH Antagonist: Study on the Antihypertensive Effectˇ± J. Med. Chem. (pending submission)

Lo, H. Y.*; Nemoto, P. A.; Kim, J. M.; Hao, M-H.; Qian, K. C.; Farrow, N. A.; Albaugh, D. R.; Fowler, D. M.; Schneiderman, R. D.; August, E. M.; Martin, L.; Hill-Drzewi, M.; Pullen, S. R.; Takahashi, H.; De Lombaert, S. ˇ°Benzimidazolone as Potent Chymase Inhibitor: Modulation of Reactive Metabolites Formation in the Hydrophobic (P1) Regionˇ± Bioorg. Med. Chem. Lett. 2011, 21 (15), 4533- 4539.

Ingraham, R. H.; Gless, R. D.; Lo. H. Y. ˇ°Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditionsˇ± Current Medicinal Chemistry, 2011, 18 (4), 587-603

President and CEO, Synovel Laboratory LLC. (USA), 2014-present

Associate Vice President of Research,KBP Biosciences Co. Ltd.(China) 2012-2013

Principal Scientist,Boehringer Ingelheim Pharmaceuticals Inc. (USA),2008-2012

Postdoc,The Ohio State University,2000-2002

Ph.D.,The Chinese University of Hong Kong ,1999

B.S., Hong Kong Bap tist University, 1996